Ginkgo Bioworks/$DNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ginkgo Bioworks
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Ticker
$DNA
Sector
Primary listing
NYSE
Employees
834
Headquarters
Website
Ginkgo Bioworks Metrics
BasicAdvanced
$589M
-
-$5.86
1.51
-
Price and volume
Market cap
$589M
Beta
1.51
52-week high
$16.85
52-week low
$5.00
Average daily volume
1.6M
Financial strength
Current ratio
5.408
Quick ratio
5.137
Long term debt to equity
69.961
Total debt to equity
69.961
Interest coverage (TTM)
-3,135.87%
Profitability
EBITDA (TTM)
-230.792
Gross margin (TTM)
78.99%
Net profit margin (TTM)
-136.56%
Operating margin (TTM)
-127.71%
Effective tax rate (TTM)
0.28%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-12.90%
Return on equity (TTM)
-43.59%
Valuation
Price to revenue (TTM)
2.478
Price to book
0.96
Price to tangible book (TTM)
1.08
Price to free cash flow (TTM)
-2.086
Free cash flow yield (TTM)
-47.94%
Free cash flow per share (TTM)
-5.096
Growth
Revenue change (TTM)
25.21%
Earnings per share change (TTM)
-67.42%
3-year revenue growth (CAGR)
-24.63%
3-year earnings per share growth (CAGR)
-58.06%
Bulls say / Bears say
Ginkgo’s Cell Engineering revenue increased 8% to $39 million in Q2 2025, fueled by growth from biopharma and government clients, underscoring steady demand for its main platform. (Reuters)
The company hit its $250 million annualized cost-cutting target three months early in Q2 2025, sharpening its trajectory toward Adjusted EBITDA breakeven by 2026. (Reuters)
As of June 30, 2025, Ginkgo had $474 million in cash and marketable securities, ensuring strong liquidity to support ongoing operations and future investments. (BioSpace)
Ginkgo’s Biosecurity revenue dropped by half to $10 million in Q2 2025 from $20 million a year ago, signalling ongoing volatility in its government-dependent segment. (Reuters)
Total revenue for Q2 2025 decreased 11% year-over-year to $50 million from $56 million, highlighting short-term demand challenges. (Reuters)
Despite progress, Ginkgo posted a GAAP net loss of $60 million in Q2 2025, pointing to its continued lack of profitability. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ginkgo Bioworks stock?
Ginkgo Bioworks (DNA) has a market cap of $589M as of September 17, 2025.
What is the P/E ratio for Ginkgo Bioworks stock?
The price to earnings (P/E) ratio for Ginkgo Bioworks (DNA) stock is 0 as of September 17, 2025.
Does Ginkgo Bioworks stock pay dividends?
No, Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Ginkgo Bioworks dividend payment date?
Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Ginkgo Bioworks?
Ginkgo Bioworks (DNA) has a beta rating of 1.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.